Archives
-
Bestatin, Angiotensin III, and Brain Neuronal Signaling
2026-10-08
The 1987 study by Harding and Felix used aminopeptidase inhibition, peptide analogs, and neuronal recordings to test whether angiotensin II must be converted to angiotensin III before producing activity in the rat brain. Its findings support a sequential processing model, while also showing why inhibitor effects should be interpreted as evidence about peptide handling rather than as definitive proof of a single enzyme pathway.
-
Rapamycin and mTOR Signaling: Evidence and Limits
2026-10-07
A source-grounded overview of Rapamycin (Sirolimus) as an mTOR research tool, emphasizing findings from a mouse spermatogonial-cell study, evidence strength, conceptual applications, and translational limitations.
-
Anti-CD4 Antibody (Ibalizumab) Evidence Guide
2026-10-07
This evidence guide places Anti-CD4 Antibody (Ibalizumab) in context with a 2026 preclinical study of in situ programmed CAR macrophages. The study supports a GPC3-directed CAR-M design in hepatocellular carcinoma models, but it does not test ibalizumab, the F1001 product, or clinical treatment outcomes.
-
YZ462 Targets MRSA Through Membrane Disruption
2026-10-06
Guo and colleagues report YZ462 as a heteroaromatic-aryl small molecule with activity against methicillin-resistant Staphylococcus aureus (MRSA), including effects on bacterial membranes, endogenous reactive oxygen species, and biofilms. The study supports YZ462 as a promising preclinical lead, while its findings remain bounded by limited reported detail on strain diversity, mechanism specificity, pharmacology, and clinical translation.
-
SB 431542: From ALK5 Biology to Translation
2026-10-06
A source-grounded perspective on how SB 431542 can clarify TGF-β pathway dependence across vascular, oncology, and immunology models while keeping mechanistic claims aligned with evidence strength.
-
Tofacitinib Repairs RA Macrophage Dysfunction
2026-10-05
A 2026 study identifies GM-CSF-reprogrammed rheumatoid arthritis macrophages as an inflammatory and metabolically dysregulated state marked by mitochondrial oxidative stress and fragmentation. Its central finding is that tofacitinib broadly reverses this phenotype through GM-CSFRα and STAT5-associated mechanisms, whereas selected metabolic interventions and established cytokine-directed comparisons had more limited effects.
-
Endogenous Melatonin in LPS-Activated Macrophages
2026-10-05
The reference study reports that LPS-induced, M1-like macrophage activation is accompanied by increased endogenous melatonin production through a TLR4/TRIF–IRF3–Aanat axis. Its findings suggest that locally produced melatonin may act as a self-limiting response that reduces inflammatory polarization, oxidative stress, and apoptosis, although the conclusions remain primarily in vitro.
-
Endogenous Melatonin in LPS-Activated Macrophages
2026-10-04
This overview addresses five questions about the principles, study design, evidence strength, pathway interpretation and limitations of research linking endogenous melatonin with LPS-induced M1-like macrophage responses. It separates reported findings from interpretation and does not treat a supplier listing as evidence for biological outcomes.
-
GI 254023X: Mapping ADAM10 Evidence
2026-10-03
GI 254023X is a selective ADAM10 inhibitor whose reported effects span sheddase activity, Notch1 signaling modulation, and endothelial barrier protection. This evidence-focused analysis distinguishes direct findings from interpretation and explains why partial-inhibition logic from BACE research cannot be transferred uncritically to ADAM10 biology.
-
Chloroquine in Cancer Therapy: Evidence and Methods
2026-10-02
The 2024 review by Liu and colleagues organizes the anticancer pharmacology of Chloroquine around both autophagy-dependent and autophagy-independent mechanisms. Its practical contribution is to connect lysosomal biology, apoptosis, necroptosis, combination treatment, toxicity, and formulation research while emphasizing that mechanistic activity does not automatically establish clinical efficacy.
-
TAK-242 for TLR4–Autophagy Research
2026-10-01
TAK-242 (Resatorvid) gives researchers a rapid, titratable way to test whether TLR4 drives inflammatory cytokine release, macrophage autophagy, or neuroinflammatory phenotypes. This workflow translates evidence from Entamoeba histolytica peroxiredoxin research into practical LPS, pathogen-associated stimulus, and brain-inflammation assay designs.
-
N-MYC/eIF4G1 in inv(16) Acute Myeloid Leukemia
2026-10-01
Peramangalam et al. identify an N-MYC-driven survival program in inv(16) acute myeloid leukemia, linking a previously unrecognized MYCN enhancer to eIF4G1 expression and leukemic maintenance. The study also positions CBFβ-SMMHC-directed perturbation as a useful way to investigate this regulatory axis in cellular and patient-derived models.
-
N-MYC–eIF4G1 Survival Axis in inv(16) AML
2026-09-30
Peramangalam et al. identify a previously unrecognized MYCN enhancer and establish an N-MYC–eIF4G1 survival program in inv(16) acute myeloid leukemia. By integrating pharmacologic, transcriptional, enhancer, cellular, primary-sample, and xenograft evidence, the study explains how CBFβ-SMMHC disruption can expose a subtype-specific leukemia dependency.
-
Standardized Whole-Blood Stimulation for Immunometabolism
2026-09-30
Zhao and colleagues present a standardized whole-blood stimulation protocol that combines pathogen-relevant immune challenges with pharmacological metabolic modulation and cytokine measurement. The framework preserves donor blood complexity while improving the reproducibility and interpretability of cohort-scale immunometabolism studies.
-
Standardized Whole-Blood Stimulation and Immunometabolism
2026-09-29
The reference study presents a standardized whole-blood stimulation protocol for measuring how metabolic interventions shape cytokine responses to innate immune and microbial stimuli. Its main contribution is a reproducible framework that preserves the complexity of human blood while enabling controlled analysis of immunometabolic regulation in cohort and translational studies.